Dr. Khan is Associate Professor and Director of Radiation Immuno-Oncology in the department of Radiation Oncology, Emory University. He is also the co-leader of the Immuno-Oncology program at Winship, and serves on the phase I clinical trials working group.
Dr. Khan is a nationally and internationally renowned for his work with radiation abscopal effects and for the management of skin cancers, lymphoma, hematological malignancies, lung cancer, pediatrics, and prostate cancer. He leads several clinical trials as a PI, including 2 current trials focusing on a deeper understanding of interactions between radiation and immunotherapy to improve outcomes for patients with melanoma, NSCLC, and myeloma.
Dr. Khan was one of the first physicians to adopt radiation and immunotherapy combinations in the management of patients with cancer.
The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.
Zachary S. Buchwald, MD, PhD, has training in both radiation oncology and immunology. His PhD research focused on developing immunotherapies that can ameliorate inflammatory, erosive bone diseases. His current interests include modulating T-cell activity for therapeutic benefit in cancer using both immunotherapy and radiation.
Dr. Mourad is the Medical Director of the department of Radiation Oncology at Erlanger Medical Center, University of Tennessee - College of Medicine Chattanooga. He is an expert in head and neck tumors, AIDS-related tumors, virus-induced malignancies (HIV/HPV/EBV), and heterotopic ossification. Dr. Mourad has mastered the utilization of various radiation therapy modalities as a means of delivering highly targeted radiation, allowing for precision treatment, including in patients who have had prior radiation.
Dal-RéR, RossJS, MarusicA. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. J Clin Epidemiol2016;75:100–107.
Dal-RéRRossJSMarusicA. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. J Clin Epidemiol2016;75:100–107.